Method for assisting examination of late relapse of ER-positive breast cancer and method for screening therapeutic drugs

By detecting ELEANOR expression and other biomarkers, combined with FISH and PCR technology, the prediction problem of postoperative recurrence risk of breast cancer is solved, providing accurate treatment choices and screening methods, reducing the risk of recurrence and treatment side effects, and improving the breast The therapeutic effect of cancer.

CN118922562APending Publication Date: 2024-11-08JAPANESE FOUND FOR CANCER RES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380029283.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-11
Filing Date
2023-04-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art cannot effectively predict the risk of recurrence after breast cancer surgery, especially ER-positive breast cancer, which makes it difficult to adjust treatment in a timely manner and increases the risk of recurrence.

Method used

By detecting ELEANOR expression, we can determine the risk of recurrence in breast cancer patients. Combining the expression of ER, PgR, HER2 and Ki67, we provide examination kits and therapeutic drug screening methods. We use FISH probes and PCR primers to detect ELEANOR to screen compounds that inhibit ELEANOR expression as Treatment medication.

Benefits of technology

Be able to accurately judge patients who need to prolong endocrine therapy, reduce the risk of recurrence, provide early detection and treatment opportunities, reduce treatment side effects, and improve the prediction accuracy and treatment effect of breast cancer recurrence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118922562A_ABST
    Figure CN118922562A_ABST
Patent Text Reader

Abstract

The breast cancer relapses in the night period after more than 5 years after the operation. If a marker for determining the risk of late relapse can be found, it is possible to contribute to the early discovery and early treatment of relapse. The inventor of the invention finds that the expression of the ELANOR is related to the recurrence of breast cancer by analyzing a clinical sample. By analyzing the expression of the ELANOR of the breast cancer primary lesion, the risk of recurrence in the late period can be examined. In addition, the ELANOR expression can also be used as an index to screen breast cancer treatment drugs. In addition, siRNA and LNA which inhibit the expression of the ELANOR can also be used as a therapeutic drug for breast cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a recurrence prediction marker and a test kit for breast cancer, and in particular to a marker for predicting late recurrence of ER-positive breast cancer. In addition, the present invention relates to a method for screening therapeutic drugs using the marker as an indicator. Background Art

[0002] The number of breast cancer cases is on the rise both in Japan and overseas. In Japan, breast cancer ranks first among female cancer cases, with approximately 94,000 cases (2018 statistics) and approximately 15,000 deaths (2019 statistics). Globally, the number of breast cancer patients is also large, with more than 2.2 million patients in 2020.

[0003] Like other cancers, breast cancer treatment includes surgery, radiotherapy, and drug therapy, and surgical removal of the cancer is the basic procedure. In addition to staging, breast cancer is also classified into subtypes based on the characteristics of cancer cells such as the expression of estrogen receptors (ER) and progesterone receptors (PgR) as hormone receptors, and epidermal growth factor receptor type 2 (HER2), and treatment guidelines are established. This is because if the hormone receptor is positive, endocrine therapy is often effective.

[0004] About 70% of breast cancer is ER-positive, which expresses ER. Endocrine therapy that inhibits the action of estrogen is effective. However, after long-term treatment, treatment resistance will be shown, resulting in a high recurrence rate. It is known that ER-negative subtypes often relapse within 3 years, while in ER-positive subtypes, the risk of recurrence lasts for more than 5 years and up to 20 years (Non-patent Document 1). There are many cases of late recurrence that still recur 5 years after surgery, which brings mental burden to patients.

[0005] In order to evaluate the risk of breast cancer recurrence, OncoType DX (EXACT SCIENCES) has been used, which uses surgical samples to investigate 21 genes. Risk assessment using OncoType DX is very effective in establishing treatment policies, such as judging the effectiveness of anticancer drug treatment after surgery. However, OncoType DX is used to predict the probability of recurrence within 10 years and is not applicable to late recurrence cases. Although there are many cases of ER-positive late recurrence, there is no diagnostic marker that can predict recurrence of breast cancer 5 years after surgery. If the risk of late recurrence can be predicted, it will help early detection and early treatment of recurrence. In order to achieve the best medical treatment for breast cancer, it is hoped that appropriate diagnosis, prognosis prediction and treatment can be established.

[0006] Prior art literature

[0007] Non-patent literature

[0008] Non-patent literature 1: Pan H., et al. N., Engl. J. Med. 2017, Vol. 377, pp. 1836-46.

[0009] Non-patent literature 2: Tomita S., et al., Nat. Commun. 2015; 6: 6966.

[0010] Non-patent literature 3: Yamamoto T., et al., Sci Rep 2018; 8: 15202.

[0011] Non-patent literature 4: Abdalla MOA et al., Nat. Commun. 2019; 10: 3778.

[0012] Non-patent document 5: Goss PE, & Chambers AF, Nat. Rev. Cancer 2010, Vol. 10, pp. 871-877. Summary of the invention

[0013] Technical problem to be solved by the invention

[0014] The present invention aims to provide a method for selecting postoperative treatment by providing a test kit and a test method for determining the risk of late recurrence. In addition, the present invention aims to provide a method for screening therapeutic drugs targeting markers associated with late recurrence by discovering markers associated with late recurrence.

[0015] Technical solutions for solving technical problems

[0016] The present invention relates to the following test methods, test kits, and methods for screening therapeutic drugs.

[0017] (1) A method for assisting the examination of late recurrence of breast cancer, which detects the expression of ELEANOR in a primary lesion and, when the expression of ELEANOR is high, determines that the risk of late recurrence is high.

[0018] The inventors of the present invention have found that ELEANOR expression is an independent risk factor for recurrence in breast cancer patients. In the case of positive ELEANOR expression, the risk of recurrence is high 5 years after surgery.

[0019] (2) The test assisting method according to (1), characterized in that the expression of estrogen receptor (ER) is detected.

[0020] For ER-positive patients with a high risk of recurrence, it is recommended to extend postoperative endocrine therapy from 5 years to 10 years after surgery. However, endocrine therapy has side effects such as menopausal symptoms, joint pain, and thrombosis, and long-term internal treatment can also cause stress to patients. Therefore, ELEANOR negative can be used as a criterion for judging whether endocrine therapy does not need to be extended. This method can be used as a criterion for judging patients who need extension and those who do not.

[0021] (3) The examination auxiliary method according to (2), characterized in that the expression of progesterone receptor (PgR), epidermal growth factor receptor type 2 (HER2), and Ki67 is detected.

[0022] In particular, the risk of late recurrence is high in the Luminal B subtype, so by examining ELEANOR expression and analyzing the factors of these Luminal subtypes, it will be possible to more accurately determine whether to extend endocrine therapy.

[0023] (4) A test kit for late recurrence risk of breast cancer, comprising a reagent for detecting ELEANOR expression.

[0024] (5) The test kit according to (4), characterized in that the above reagents are FISH probes and / or PCR primers.

[0025] As described above, since ELEANOR is a risk factor for late recurrence of breast cancer, if it can be examined using FISH probes or PCR primers, the risk of late recurrence of breast cancer can be detected.

[0026] (6) A method for screening a drug for treating breast cancer, comprising culturing cells expressing ELEANOR with a candidate compound, and screening the drug using changes in ELEANOR expression, ER and / or CD44 expression as indicators.

[0027] (7) The screening method according to (6), characterized in that the cells expressing ELEANOR are LTED cells.

[0028] The inventors of the present invention have found that ELEANOR expression is associated with the risk of late recurrence of breast cancer, and is also associated with ER expression or CD44 expression. Therefore, if the expression of these molecules can be used as an index to screen compounds, it is possible to obtain compounds that are therapeutic drugs for late recurrence of breast cancer. In addition, since ELEANOR expression is also associated with CD44 expression, which is a breast cancer stem cell marker, it is highly possible to obtain therapeutic drugs that target breast cancer stem cells.

[0029] (8) A pharmaceutical composition which is a therapeutic drug for breast cancer, wherein the pharmaceutical composition contains a compound that inhibits the expression of ELEANOR as an active ingredient.

[0030] (9) The pharmaceutical composition according to (8), wherein the compound is a nucleic acid drug.

[0031] As shown below, ELEANOR expression can be inhibited by nucleic acids such as siRNA and LNA. Therefore, these nucleic acids can be used as therapeutic drugs for late recurrence of breast cancer.

[0032] (10) A method for treating late recurrence of breast cancer, which is used to treat late recurrence of breast cancer, the method being characterized in that the expression of ELEANOR in the primary lesion of the subject is detected using the auxiliary examination method described in any one of (1) to (3) or the examination kit described in (4) or (5), and when it is determined that the risk of late recurrence is high, treatment is performed using the pharmaceutical composition described in (8) or (9). BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1A The ELEANOR scores of 178 primary breast cancers are shown. Score 1 (Score 1) and score 2 (Score 2) are defined as ELEANOR positive.

[0034] Figure 1B : is a mosaic plot showing the ratio of ELEANOR positive and negative patients by breast cancer subtype. The numbers in the figure represent the actual number of patients classified into each category (total n=178).

[0035] Figure 1C Representative HE staining images (upper), ER immunohistochemical staining images (middle), and RNA FISH images of corresponding samples (lower) of cases with ELEANOR scores of 0 to 2 (from left to right).

[0036] Figure 1D This is a mosaic image obtained by analyzing the correlation between the ELEANOR score and the ER expression level obtained by immunohistochemical staining using the Allred scoring system. The correlation with the ratio score (left) and the intensity score (right) is shown. The Spearman rank correlation coefficient is represented by rs.

[0037] Figure 2A Kaplan-Meier survival curves showing recurrence-free survival (RFS, left) and overall survival (OS, right) in patients with ELEANOR-positive and -negative primary lesions (n=141, log-rank test).

[0038] Figure 2B Shown are the RFS of ELEANOR-positive and -negative patients with Luminal A breast cancer (left) and Luminal B breast cancer (right).

[0039] Figure 2C Lieutenant General Figure 2A The Kaplan-Meier survival curves are divided into early (left, 0-5 years or 0-8 years after surgery) and late (right, 5 or 8 years after surgery). The RFS (upper part) and OS (lower part) of ELEANOR-positive patients have a poor prognosis only in the later (right) time frame. Based on all data up to 5 or 8 years. The log-rank statistics after 5 or 8 years after surgery are based on the data of all patients who survived 5 or 8 years without recurrence.

[0040] Figure 3A The Kaplan-Meier survival curves (n=139, Wilcoxon test) show the presence or absence of ELEANOR in the primary lesion and the time until recurrence. "No. at Risk" indicates the number of patients at risk of recurrence at each time point.

[0041] Figure 3B This is a mosaic diagram showing changes in ER (left) and PgR (right) expression after metastasis. In patients whose primary lesions did not express ELEANOR (-), the frequency of ER and PgR expression becoming negative was high, and in patients whose primary lesions expressed ELEANOR (+), there was a trend to maintain ER and PgR expression. The numbers in the figure show the actual number of each group (total n = 139). The P value was calculated based on the Pearson chi-square test, showing the correlation between ELEANOR expression in the primary lesion and the negative conversion of ER and PgR.

[0042] Figure 4A This is a diagram showing the correlation between ELEANOR scores 0 to 2 and ER expression obtained by Allred score. The ER ratio score (left) and intensity score (right) in the primary lesion (upper part) and metastatic lesion (lower part) are shown.

[0043] Figure 4B It is a graph showing the correlation between ELEANOR scores 0 to 2 and PgR expression represented by Allred score. PgR ratio score (left) and intensity score (right) in primary lesions (upper part) and metastatic lesions (lower part) are shown.

[0044] Figure 5A The figure shows the results of sphere assay using HCC1428 and HCC1428-LTED cells. The figure shows the image observed by microscope (left) and the quantitative graph (right).

[0045] Figure 5BCD44, a stem cell marker, is shown in HCC1428-LTED cells in which ELEANOR2 is knocked down + / CD24 - / low FACS analysis (left) and quantitative graphs (right).

[0046] Figure 5C The graph shows the results of RT-qPCR analysis of ESR1, ELEANOR2, pa-ELEANOR, and CD44 in HCC1428 and HCC1428-LTED cells.

[0047] Figure 5D The graph shows the results of knocking down ELEANOR using ELEANOR2 LNA and pa-ELEANOR LNA, and analyzing the expression of ESR1 and CD44 by RT-qPCR.

[0048] Figure 5E The graph shows the results of immunoblotting analysis of CD44 expression caused by changes in ELEANOR expression (upper part) and the quantitative results (lower part).

[0049] Fig. 5F The inhibition of ELEANOR expression and CD44 expression in HCC1428-LTED cells were shown by FACS analysis. + The results obtained by quantifying cells (left) and the graph after quantification (right). The mode in the analysis was set to 100.

[0050] Figure 5G The graph shows the results of knocking down ESR1 and analyzing ELEANOR and CD44 mRNA by RT-qPCR.

[0051] Figure 5H The graph shows the results of knocking down ESR1, ELEANOR2, and pa-ELEANOR in HCC1428-LTED cells by siRNA or LNA, and analyzing ERα expression by immunoblotting.

[0052] Fig. 6A The results of CD44 knockdown in HCC1428-LTED cells and MCF7-LTED cells and sphere formation experiments are shown. Microscope images (left) and quantitative graphs (right) are shown.

[0053] Figure 6BThe results of transplanting HCC1428 cells or HCC1428-LTED cells into the mammary fat pad of ovariectomized mice and analyzing the proliferation are shown. The size of the tumor (left, n=8 in each group) and the tumor formed by transplanting HCC1428-LTED cells (right, top) are shown. HE staining, ER tissue immunostaining, and ELEANOR RNA-FISH images are shown (right, bottom). No tumors were formed in mice transplanted with HCC1428 cells as the parent strain.

[0054] Figure 6C The results of RT-qPCR analysis of ESR1 mRNA, ELEANOR, and CD44 mRNA in LTED cells before transplantation (in vitro) and after transplantation (in vivo) are shown.

[0055] Fig.6D RT-qPCR analysis of CD44 mRNA in various breast cancer cells.

[0056] Fig. 6E The results of transplanting each cell into mice and performing CD44 immunohistostaining are shown. The figures show representative images of each cell. Fig.6D and Fig. 6E In the study, HCC1428, MDA-MB-231, and MDA-MB-468 cells were directly transplanted into intact ovariectomized mice and allowed to form tumors.

[0057] Fig. 6F RNA-FISH images of ELEANOR and centromere 6 (left) and ELEANOR and CD44 (middle). Nuclei with overlapping signals of CEN6 or CD44 and ELEANOR were quantified (right). P values ​​were calculated using two-tailed Fisher's exact test.

[0058] Fig. 7A HE staining images of tissues with ELEANOR scores of 0 to 2 (upper part), CD44 immunohistochemical staining images (middle part), and ELEANOR FISH analysis images (lower part) are shown.

[0059] Figure 7B It is a mosaic diagram showing the correlation between the ELEANOR score and the CD44 expression obtained by tissue immunostaining. The ratio score (left) and intensity score (right) of CD44 are determined by the Allred scoring system. The numbers in the figure represent the actual number. The Spearman rank correlation coefficient is represented by rs. DETAILED DESCRIPTION

[0060] The research group of the inventors of the present invention has conducted a long-term study on a cluster of non-translated RNAs called ELEANOR (ESR1 locus enhancing and activating non-coding RNAs: ELEANORS). ELEANOR is a cluster of non-translated RNAs that can be seen in cells cultured with long-term estrogen blockage (long-term estrogen deprivation: LTED), which is a model of recurrent breast cancer that shows resistance to aromatase inhibitors. LTED cells are constructed from ER-positive breast cancer cell lines such as MCF7 and HCC1428 (Non-Patent Document 2). ELEANOR is transcribed from a topologically asociating domain (TAD) of about 1Mb (chr6: 151,750,000-152,750,000) including four genes including the ESR1 gene encoding ER. In the cell nucleus, ELEANOR aggregates around the ESR1 gene to form the ELEANOR Cloud, thereby activating the entire ELEANORTAD region. The inventors of the present invention have found that u-ELEANOR, pa-ELEANOR, and ELEANOR2 in ELEANOR are important for the formation of the ELEANOR Cloud and the transcriptional activation of genes within the ELEANOR TAD (Non-Patent Document 3).

[0061] The inventors of the present invention evaluated primary and corresponding metastatic breast cancer tissues using the clinical pathological characteristics of ELEANOR. The results showed that the expression of ELEANOR was limited to ER-positive cases, and was particularly well correlated with the expression levels of ER and PgR in metastatic lesions. It was also found that, unlike common cancers, patients with ELEANOR-positive primary lesions had an increased recurrence rate after 5 years, not within 5 years, thereby completing the present invention.

[0062] The following is a detailed description of the data, but the present invention is not limited thereto. In addition, unless otherwise specified, the experimental methods used below are based on methods commonly performed in the art.

[0063] [Analysis object]

[0064] Clinical samples obtained from two independent cohorts were used for analysis. Cohort 1 consisted of 185 patients with primary breast cancer who underwent surgery for primary lesions of 2 to 5 cm (pT2) at the Cancer Research Center Hospital from 2005 to 2006, including tumors of all pathological types. Cohort 2 consisted of 167 patients with metastatic breast cancer who underwent surgery for ER-positive primary breast cancer from 2001 to 2016 and then underwent biopsy or resection of the recurrence site. In cohort 2, a pair of tissues from the primary site and metastatic site were used for analysis.

[0065] [ELEANOR Cloud and ER expression in breast cancer tissues]

[0066] Although the chromatin control mechanism of ELEANOR in vitro has been studied, there are still many unknowns about the function of ELEANOR in vivo. Therefore, in order to explore the clinical significance of ELEANOR, 185 primary breast cancers in cohort 1 were analyzed by RNA-FISH to evaluate the expression of ELEANOR ( Figure 1A ).

[0067] RNA-FISH was performed as follows. 4 μm sections were made from resection or biopsy samples and implemented using the ZytoLight FISHTissue Implementation Kit (ZytoVision). Specifically, the slides containing the sections were heated at 70°C for 10 minutes, treated with xylene three times for 5 minutes each, rehydrated in stages with a methanol solution, washed with dH2O, incubated with a citric acid solution at 98°C for 15 minutes, and washed with dH2O. Next, the slides were treated with a pepsin solution at 37°C in a wet tray for 30 minutes, washed with 2×SSC for 5 minutes, and then washed with dH2O for 1 minute. After the slides were dehydrated, they were air-dried. Then, a probe was added that was heated at 75°C for 10 minutes to denature it. After hybridization at 37°C for 2 days, the slides were washed three times with washing solution at 37°C, dehydrated, and mounted with ProLong Diamond Antifade with DAPI (ProLongDiamond antifade containing DAPI, Thermo Fisher). The probes used included BAC probes for A SPEC ESR1 / CEN6 Dual Color Probe (ZytoVision), ELEANOR locus (RP11-450E24), and CD44 locus (RP11-790K21).

[0068] ELEANOR can be detected using probes for detecting ELEANOR disclosed in non-patent documents 2 to 4, specifically RP1-130E4 and RP3-443C4; probes for detecting ESR1 and genes in the vicinity thereof, specifically RP1-63I5, RP11-108N, and RP3-404G5; and RP11-66L11, which is not described in these documents but is used to detect ELEANOR2. In addition, other probes that can specifically detect the region can also be used.

[0069] The ELEANOR staining images were detected in the nuclei of cancer cells by FISH, and the ELEANOR was classified into score 0, score 1, and score 2 according to the size of ELEANOR. Figure 1A ). In addition, score 0 was considered ELEANOR negative (-), and scores 1 and 2 were considered ELEANOR positive (+). After excluding 7 samples that were not suitable for FISH, 58 cases (33%) were ELEANOR positive tumors ( Figure 1A ).

[0070] ELEANOR expression was confirmed in ER-positive luminal A, luminal B, and luminal HER2 breast cancers ( Figure 1B ), ELEANOR expression was not confirmed in ER-negative subtypes, HER2, and triple negative (TNBC) types. Therefore, focusing only on the ER-positive group (n=141), it was found that ELEANOR expression was significantly higher in tumors from postmenopausal patients or patients over 50 years old (Table 1).

[0071] In addition, the subtypes are defined as follows (Non-Patent Document 5). Luminal A: ER and / or PgR positive, HER2 negative, Ki67 LI ≤ 14%, grade <3; Luminal B: ER and / or PgR positive, HER2 negative, Ki67 LI ≥ 14%, grade 3; Luminal HER2: ER and / or PgR, HER2 positive; HER2: ER and PgR negative, HER2 positive; Triple negative: ER, PgR, HER2 negative.

[0072] [Table 1]

[0073]

[0074] 1 menopausal status was excluded from the analysis a Unknown patient and 4 Ki67 b Undetermined patients. Three patients receiving endocrine therapy were excluded from the analysis. c Patients with unknown medical history and 1 chemotherapy d and radiotherapye Patients with unknown medical history. Statistically significant (**p<0.01).

[0075] ER expression was detected by immunohistochemical staining and analyzed for correlation with ELEANOR Cloud ( Figure 1C ). In immunohistostaining (IHC), formalin-fixed paraffin-embedded samples were cut into 4 μm sections and stained using the BenchMark ULTRA (Roche) or BONDIII (Leica) automatic section staining system. Cells were considered positive when more than 1% of the nuclei were positive, and the expression level was evaluated using the Allred scoring system. The results showed that ELEANOR Cloud was correlated with ER expression. In the universal Allred scoring system for ER using immunohistostaining, the higher the ELEANOR score, the higher the proportion of ER-positive cells (ER proportion score) and the higher the ER staining intensity (ER intensity score) (Spearman rank correlation test, rs=0.30, rs=0.25, respectively). Figure 1D These results are consistent with previous in vitro observations that ELEANOR is present in LTED cells and functions to control ER overexpression through chromatin control.

[0076] In addition, immunohistostaining of PgR, CD44, and HER2, whose data are shown below, was also performed. In addition, the following antibodies were used as antibodies. Anti-ER antibody: clone SP1 (Roche or Abcam); anti-PgR antibody: clone 1E2 (Roche); anti-HER2 antibody: clone 4B5 (Roche); anti-Ki67 antibody: clone MIB-1 (DAKO); anti-CD44 antibody, polyclonal (Abcam).

[0077] [Correlation between ELEANOR expression and late recurrence of ER-positive breast cancer]

[0078] Regarding the ER-positive group (n=141) of the above-analyzed cohort, recurrence-free survival (RFS) and overall survival (OS) were evaluated ( Figure 2A ). The RFS and OS of the group of patients with ELEANOR-positive primary lesions were worse than those of the group of patients with ELEANOR-negative primary lesions. In Luminal A and Luminal B breast cancer, the RFS of ELEANOR-positive and -negative patients was analyzed. The difference between ELEANOR-positive and -negative in the ER-positive subtype was more significant in the Luminal B type, but no difference was found in Luminal A ( Figure 2B ).

[0079] Will Figure 2AThe survival curves obtained by the Kaplan-Meier method were divided into early (RFS: 0 to 5 years after surgery, OS: 0 to 8 years) and late (RFS: more than 5 years after surgery, OS: more than 8 years after surgery) time ranges for analysis ( Figure 2C ). This showed that ELEANOR positivity was a risk factor for recurrence in the later stage (log-rank test, P = 0.006), but not in the early stage (log-rank test, P = 0.67). Figure 2C Regarding OS, the results also showed that the prognosis was poor in the later period ( Figure 2C Also, although not shown here, patients with an ELEANOR score of 1 or 2 had worse RFS 5 years after surgery compared with patients with an ELEANOR score of 0.

[0080] These results indicate that ELEANOR is involved in late recurrence of ER-positive breast cancer. After multivariate analysis adjusted for disease stage and HER2 status, ELEANOR expression was an independent risk factor for recurrence in patients with ER-positive breast cancer (Table 2, Hazard Ratio, HR=2.40, P=0.014). In addition, although not shown here, after analyzing the group of patients who received endocrine therapy, it was also shown that the recurrence rate in the ELEANOR-positive patient group was high 5 years after surgery. This result suggests that ELEANOR also plays an important role in acquiring resistance to postoperative endocrine therapy.

[0081] [Table 2]

[0082]

[0083] Cl: confidence interval. Statistical significance (*P<0.05).

[0084] [Analysis of metastatic lesions]

[0085] The role of ELEANOR in recurrence was analyzed using 167 paired samples of ER-positive primary tumors and their corresponding metastatic lesions. ELEANOR expression was analyzed by FISH. The results of the analysis of the remaining 139 cases after removing 28 cases that were not suitable for FISH are shown. It can be seen that 45 cases (32%) of the primary lesions expressed ELEANOR, and 40 cases (29%) of the metastatic lesions expressed ELEANOR. Figure 2A The results shown are similar. Even in these clinical sample groups, it is also shown that patients with ELEANOR-positive primary lesions relapsed later than those with ELEANOR-negative primary lesions ( Figure 3A ). This suggests that ELEANOR is involved in late recurrence. In addition, analysis of this dataset showed that ELEANOR is overexpressed in lung metastasis.

[0086] For all patients, the changes in ELEANOR expression in primary and recurrent lesions were analyzed by FISH (Table 3). The metastatic lesions of 116 of 139 cases (83%) maintained the same ELEANOR status as the primary lesions, and 31 of 45 cases (69%) were also ELEANOR positive after metastasis. There was no statistically significant difference in patients after adjuvant therapy including aromatase inhibitor therapy due to the small number of samples, but ELEANOR expression increased slightly (Pearson chi-square test, P = 0.1).

[0087] [Table 3]

[0088]

[0089] It has been reported that changes in the status of hormone receptors (ER, PgR) after metastasis affect prognosis, and patients whose ER status becomes negative tend to have a worse prognosis than those who maintain receptor positive. Therefore, the correlation between changes in hormone receptor expression and the expression of ELEANOR in the primary lesion was analyzed. The results showed that in the group of patients whose primary lesions were ELEANOR-positive, the frequency of ER and PgR expression status changing from positive to negative after metastasis was low ( Figure 3B , Pearson chi-square test, P = 0.012, P = 0.036).

[0090] Next, the expression status of ELEANOR and breast cancer biomarkers was analyzed in primary lesions and metastatic lesions (Table 4). The expression of ELEANOR in metastatic lesions was significantly correlated with PgR positivity and HER2 negativity, but no correlation was found in primary lesions.

[0091] [Table 4]

[0092]

[0093] a Five primary cases and two metastatic cases with undetermined Ki67 were excluded from the analysis.

[0094] Statistically significant (**p<0.01).

[0095] Detailed immunostaining analysis using the Allred scoring system revealed that the primary lesion ( Figure 4A , upper left, rs = 0.23, P = 0.006), in metastatic lesions, the ELEANOR score was more strongly correlated with the ER ratio score ( Figure 4A Lower left, rs = 0.38, P < 0.001). In addition, the ER signal intensity was measured and analyzed to show that ( Figure 4A Right), ELEANOR is more strongly correlated with ER in metastatic lesions than in primary lesions ( Figure 4A Lower right): rs = 0.49, primary lesion ( Figure 4A Upper right): rs=0.37). In addition, a positive correlation was detected between ELEANOR and PgR in the metastatic site (ratio score: rs=0.29, intensity score: rs=0.23) ( Figure 4B , lower part), but no relevant information was found in the primary lesion ( Figure 4B , upper part). These results indicate that ELEANOR activates ESR1 gene expression as a transcription factor after metastasis and activates target genes including PgR gene. Therefore, ELEANOR has the possibility of participating in the metastasis of breast cancer through activation of ER signaling pathway. These results indicate that compounds that inhibit ELEANOR expression can inhibit metastasis or deterioration.

[0096] [Correlation between ELEANOR and CD44 expression and breast cancer stem cells]

[0097] It is generally believed that late recurrence of breast cancer is caused by various factors such as tumor dormancy, cancer stem cell nature, and endocrine therapy resistance. If ELEANOR is related to stem cell nature, then inhibition of ELEANOR expression may lead to the elimination of breast cancer stem cells. Therefore, the correlation between cancer stem cells and ELEANOR was analyzed. + / CD24 - / low It is regarded as a biomarker for breast cancer stem cells. As an ER-positive breast cancer model, HCC1428 and MCF7 cell lines were used to analyze breast cancer stem cells, and as an in vitro model of ELEANOR high expression showing endocrine therapy resistance, LTED cells of these cell lines were used to analyze breast cancer stem cells. HCC1428 and HCC1428-LTED cells were used for sphere formation experiments. HCC1428-LTED cells showed a higher sphere formation ability than HCC1428 cells, indicating that breast cancer stem cells exist in HCC1428-LTED cells ( Figure 5A ).

[0098] The ELEANOR2 RNA, which is the most abundant in ELEANOR, was knocked down by LNA, and the CD44 / CD24 expression was analyzed by FACS ( Figure 5B ). The following LNAs were transfected using RNAiMAX (invitrogen) and analyzed 48 hours later. By knocking down ELEANOR2, breast cancer stem cells (CD44 + / CD24 - / low ) was significantly reduced.

[0099] ELEANOR2-LNA: TTTGGCCACATTGGAA (sequence number 1)

[0100] LNA-Control: AACACGTCTATACGC (SEQ ID NO. 2)

[0101] In addition, the expression of ESR1, ELEANOR, and CD44 was analyzed by RT-qPCR using the following primers in HC1428 and HC1428-LTED cells. In RT-qPCR, total RNA was purified from cultured cells using NucleoSpin RNA / protein kit (MACHEREY-NAGEL) and reverse transcribed using ReverTra Ace qPCR RT Master Mix (TOYOBO). RT-qPCR was performed using SYBR Green using ABI Prism 7500 (ABI).

[0102] ESR1-S: CTCCTCCTCATCCTCTCCCA (serial number 3)

[0103] ESR1-AS: CTTTGGTCCGTCTCCTCCAC (sequence number 4)

[0104] pa-ELEANOR-S:TAAGCCAATGTCAGGGCAAG (serial number 5)

[0105] pa-ELEANOR-AS:TCCCGAGCTCATATGCATTAC (serial number 6)

[0106] ELEANOR2-S: CGCCTCTGAAGTTTGCATC (serial number 7)

[0107] ELEANOR2-AS: GTCTGGGTGCCACTGTTTG (sequence number 8)

[0108] CD44-S: CCCAGATGGAGAAAGCTCTG (SEQ ID NO: 9)

[0109] CD44-AS: GTTGTTTGCTGCACAGATGG (SEQ ID NO. 10)

[0110] In addition, the quantification of ELEANOR can also be performed using probes of sequence numbers 11 to 40 disclosed in non-patent documents 2 and 4 that detect ESR1, RMND1, C6orf211, and CCDC170 contained in the region. In addition, any probe that can detect genes or untranslated RNA contained in the region can be used.

[0111] RT-qPCR analysis results showed that CD44 mRNA, ELEANOR2 and pa-ELEANOR, which are ELEANOR-specific sequences, were overexpressed in HCC1428-LTED cells compared with HCC1428 cells ( Figure 5C ). Next, the ELEANOR expression was inhibited by using ELEANOR-specific LNA of sequence number 1 and sequence number 41 to investigate whether there was a change in CD44 expression. CD44 mRNA expression was reduced by knockdown of these ELEANORs ( Figure 5D ).

[0112] pa-ELEANOR-LNA: GTGCCAGACTCCGATA (SEQ ID NO. 41)

[0113] We investigated whether CD44 expression also changes at the protein level. We compared CD44 expression between HCC1428 and HCC1428-LTED cells. We introduced LNA (sequence number 1) that inhibits ELEANOR expression and siRNA (Thermo Fischer) that inhibits CD44 expression into HCC1428-LTED cells, and analyzed CD44 expression by Western blotting ( Figure 5E ). The results of Western blot analysis showed that the expression of CD44 protein was also correlated with the expression of ELEANOR. In addition, by introducing LNA of sequence number 1 into HCC1428-LTED cells to knock down ELEANOR, FACS was used to analyze whether there was also a change in the expression of CD44 on the cell surface. The results showed that by knocking down ELEANOR, CD44 + Cell reduction ( Fig. 5F ).

[0114] Although the data are not shown here, the same results as above were obtained in MCF7-LTED, that is, LTED cells had high spheroidization ability and high expression of CD44 mRNA and protein. However, although the effect of knocking down ELEANOR on CD44 expression in MCF7-LTED cells was significant at the mRNA level, there was almost no effect at the protein level. This is believed to be due to the low CD44 protein level in MCF7-LTED cells. However, FACS analysis of MCF7-LTED cells showed that ELEANOR2 knockdown resulted in a decrease in CD44 + The number of cells decreased slightly but significantly. These data suggest that the function of ELEANOR is maintained in different cell lines and that ELEANOR is involved in the increased expression of the CD44 gene.

[0115] Next, we inhibited the expression of ESR1 by using siRNA (Sigma) against ESR1 and analyzed the expression of ELEANOR and CD44. No decrease in the expression of any RNA was observed ( Figure 5G ). In addition, when the expression of ESR1 and ELEANOR was knocked down and the expression of ER was analyzed, ER expression was inhibited regardless of which one was knocked down ( Figure 5H ). Although knockdown of ESR1 mRNA and ELEANOR suppressed the expression of ER protein, the expression of CD44 mRNA was not affected by knockdown of ESR1 mRNA. These results exclude the possibility that ER protein is involved in the activation of CD44 expression in LTED cells.

[0116] In addition, we investigated whether the upregulation of CD44 caused by ELEANOR directly contributes to the spheroid formation ability. After knocking down CD44 in LTED cells by siRNA (Thermo Fisher), it was found that the spheroid formation ability of HCC1428-LTED and MCF7-LTED cells was significantly inhibited by CD44 knockdown ( Fig. 6A ). These findings suggest that ELEANOR is involved in cancer stem cell differentiation through increased CD44 expression.

[0117] [Analysis of Xenograft]

[0118] To investigate the function of ELEANOR in vivo, the ovaries of NOD / SCID mice were removed, and HCC1428 cells and HCC1428-LTED cells were xenotransplanted into the mammary fat pad to evaluate the tumor formation ability (n=8 in each group). None of the mice transplanted with HCC1428 cells as the parent strain developed palpable tumors. On the other hand, no tumors were observed in mice transplanted with HCC1428-LTED cells ( Figure 6B , upper left and right). In HCC1428-LTED cells transplanted into mice, ELEANOR expression was confirmed by FISH ( Figure 6B , lower right). Moreover, RT-qPCR showed that the CD44 mRNA level and ESR1 and ELEANOR expression of HCC1428-LTED cells increased in the cells after transplantation into mice compared with the levels of cells cultured in vitro before transplantation ( Figure 6C ).

[0119] In addition, HCC1428, MDA-MB-231 and MDA-MB-468 cells established from triple-negative breast cancer patients were directly transplanted into intact mice, and HCC1428-LTED cells were transplanted into ovariectomized mice, and the CD44 expression of the tumors was analyzed ( Fig.6D , E). In tumors derived from HCC1428-LTED cells transplanted into ovariectomized mice, CD44 mRNA ( Fig.6D ) and protein ( Fig. 6E ) was expressed at a higher level than that of tumors derived from HCC1428 cells transplanted into intact mice. In addition, CD44 mRNA in transplanted HCC1428-LTED showed similar expression to that in the triple-negative cell line MDA-MB-231 ( Fig.6D ) but showed higher expression than MDA-MB-231 cells at the protein level and the same level as other triple-negative MDA-MB-468 cells ( Fig. 6E ).

[0120] To investigate whether the increased expression of CD44 occurs near the ELEANOR Cloud, we used tumors derived from HCC1428-LTED cells xenografted in ovariectomized mice to simultaneously visualize the transcription sites of ELEANOR and CD44 by RNA-FISH. The results showed that the proportion of CD44 and ELEANOR overlapped and stained was higher than that of the control centromere 6 ( Fig. 6F ). It is believed that ELEANOR up-regulates the expression of CD44 gene by providing a nuclear environment with high transcriptional activity.

[0121] Next, to investigate whether the expression of CD44 in clinical samples is related to the expression of ELEANOR, the expression of CD44 in primary ER-positive breast cancer tissues (n=141) with a stage of pT2 (2.0 < maximum diameter ≤ 5.0 cm) was analyzed. In the representative immunohistochemical staining analysis of CD44, more CD44-positive cells were observed in the ELEANOR+ group (scores 1 and 2) ( Fig. 7A ).

[0122] The Allred scoring system showed that there was a very weak correlation between the ELEANOR score and the proportion score and intensity score of CD44 expression ( Figure 7B , rs = 0.19, P = 0.02 and 0.20, P = 0.02, respectively). In addition to the analysis of cultured cell lines (Figure 5), the results obtained from patient tissues showed that in addition to ER signaling activation, CD44 gene activation maintained the stemness of breast cancer, allowing ELEANOR to participate in late recurrence.

[0123] Based on the above results, a method for checking the risk of late recurrence, a test kit, and a screening method for medicine are provided. As a specific inspection method, the ELEANOR of the primary focus of breast cancer is inspected, and when it is ELEANOR positive, it is judged that the risk of late recurrence is high. At present, follow-up diagnosis is performed 5 to 10 years after surgery, and treatment ends after 5 years, but in the case of high risk of late recurrence, follow-up observation after surgery is still further performed for a long time, so that even in the case of recurrence, it can be found and treated as early as possible (early stage), and in addition, the following strategy can also be adopted, that is, treatment is still continued after 5 years to prevent recurrence and reduce the risk of recurrence. In addition, for the patient group with low risk of late recurrence, as before, follow-up diagnosis 5 to 10 years after surgery can be performed. Although there is currently an inspection to determine the treatment policy after surgery, this inspection method can identify patients with high risk of late recurrence, and is useful as a method for inspecting the risk of refractory recurrence breast cancer.

[0124] The test of the present invention may be any method as long as it can detect ELEANOR. As a method for detecting ELEANOR, it may be detection of ELEANOR-specific RNA such as RNA-FISH, ELEANOR2, pa-ELEANOR using RT-PCR, quantification using RT-qPCR, or detection of the expression of ESR1 and the like, which are genes included in the topological domain of ELEANOR, at the RNA level by RT-PCR or RT-qPCR, or at the protein level by ELISA, protein blotting, etc. As reagents for these tests, for example, in the case of RNA-FISH, a FISH probe is used as a set of reagents, and in the case of PCR, a primer and the like are used as a set of reagents, and a kit containing the reagents required for the test can be prepared.

[0125] In addition, based on the above findings, the inhibition of ELEANOR expression can be used as an indicator to screen for pharmaceutical compositions for treating late recurrent breast cancer or reducing the risk of recurrence. Specifically, candidate compounds are added to the culture medium of cells that highly express ELEANOR, such as LTED cells, and compounds that inhibit ELEANOR expression are selected. In addition, siRNA, LNA, etc. that inhibit the expression of ELEANOR can be used as nucleic acid drugs.

Claims

1. A method for assisting the detection of late recurrence of breast cancer, characterized in that: Detection of ELEANOR expression in primary lesions, When the ELEANOR expression is high, the risk of late recurrence is determined to be high.

2. The inspection assisting method according to claim 1, characterized in that: Detection of estrogen receptor ER expression.

3. The inspection assisting method according to claim 2, characterized in that: The expressions of progesterone receptor PgR, epidermal growth factor receptor type 2 HER2 and Ki67 were detected.

4. A test kit for the risk of late recurrence of breast cancer, characterized in that: Contains reagents for detecting ELEANOR expression.

5. The test kit according to claim 4, characterized in that: The reagents are FISH probes and / or PCR primers.

6. A method for screening drugs for treating breast cancer, characterized in that: Cells expressing ELEANOR are cultured with candidate compounds. Drugs are screened using changes in ELEANOR expression, ER and / or CD44 expression as indicators.

7. The screening method according to claim 6, characterized in that The cells expressing ELEANOR are LTED cells.

8. A pharmaceutical composition, which is a therapeutic drug for breast cancer, wherein the pharmaceutical composition is characterized in that: The active ingredient is a compound that inhibits the expression of ELEANOR.

9. The pharmaceutical composition according to claim 8, characterized in that The compound is a nucleic acid drug.